



Enabling Technologies
CONSORTIUM™

NEWSLETTER

Volume I - Summer 2016

A Note from the Chair

Welcome to the very first issue of the Enabling Technologies Consortium™ (ETC) newsletter! As a new consortium we want to use this newsletter as a way to communicate who we are, what we do and share with you an update on the enabling technologies that are the focus of the group.

ETC formed in August 2015, originating as a Working Group within the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium). Our consortium of pharmaceutical and biotech companies is focused on the optimization of technologies that enable pharmaceutical development. Our goal is to simplify and accelerate the process for establishing collaborations by standardizing the procedures and agreements under which they operate; to proactively identify high-value opportunities to deliver innovative technologies where the business case is compelling and collaboration with the broader external community (vendor, academic, government) is required. Our consortium enables its members and organizations to collaborate precompetitively and to move beyond the cumbersome, time-consuming, repetitive, and costly process currently employed to organize joint activities and focus on a more sustainable and efficient process to enable these optimization efforts.

The ETC had a successful first Board of Directors meeting in June 2016. At nine member companies and growing, the Board actively engaged in discussing the critical deliverables for the consortium, building our 3-5 year plan and identifying opportunities for expansion and outreach. Significant progress was also made on our foundational documents that establish the collaboration framework (membership and operational agreements). However, the core of the discussion was the exciting and productive talks around our current enabling technology efforts and how the Board of Directors can actively support the project teams and their deliverables. With a focus on these enabling technologies we have made significant advances in completion and submission of Requests for Information (RFIs) from the Personal Parallel Reactor, Crystallization and Purification teams, while substantial publications are expected from our technology teams involved in Drying, Model Sharing and HTE solid dosing.

We intend to feature our articles highlighting these and other projects in this newsletter so we can share and learn together, identify further application areas and trigger further innovative ideas for collaboration.

This is a very exciting time for the ETC as we grow our organization and bring new technologies to fruition for the industry. I would like to thank everyone for their engagement and active participation and I hope you enjoy the newsletter!

Regards,
Margaret Faul
Chair, Enabling Technologies Consortium
Amgen, Inc

AbbVie • Amgen • AstraZeneca • Biogen • Bristol-Myers Squibb • Celgene • Eli Lilly
Merck & Co. (USA) • Takeda



Enabling Technologies Consortium™ (ETC) Confirms Chair and Vice Chair

After a recent vote by the Board of Directors, Margaret Faul (Amgen) was confirmed as the first Chair of ETC (see Margaret's note on page one). Chris Welch (Merck & Co. USA) has been confirmed as Vice Chair. ETC members extend congratulations to both Margaret and Chris on their new leadership roles!



Margaret Faul
ETC Chair
Amgen



Chris Welch
ETC Vice Chair
Merck & Co.
(USA)

ETC Workshop

ETC will be conducting a one day member workshop on November 3, 2016 in Philadelphia, PA. The workshop will provide an opportunity for individual project teams to meet in person during morning breakout sessions. Teams will then present their progress and proposals for new projects during a joint afternoon session which Board members are invited to attend.

Participants can register to attend the workshop using the following link <https://www.signmeup.com/4L2VHH7>

Subscription List

ETC is building a subscription list for vendors to receive notifications on the release of ETC RFIs and RFPs. Members are asked to share this opportunity with their vendors by circulating the following link to the contact form:

<http://www.etconsortium.org/contact-us/>

New Committees Forming

The Enabling Technologies Consortium™ is forming two new committees to assist with promoting and publicizing the consortium. Members interested in being a part of the new writing committee or the outreach committee should contact the Secretariat info@etconsortium.org.

In the News

Press releases announcing three new requests for information (RFIs) were issued in May and July. The projects focus on a Personal Parallel Reactor, Crystallization efficiency and Next-Generation Preparative Supercritical Fluid Chromatography Instrumentation. Links to all three RFIs can be found on the ETC website using the following link

<http://goo.gl/huKZg6>



ETC Events

Workshop

At Secretariat offices in Philadelphia, PA
November 3,
2016

Board Meeting

At Secretariat offices in Philadelphia, PA
November 4, 2016



Conference

OutsourcedPharma

San Francisco, CA
November 1-2, 2016